Epic Short Squeeze Inflection Point Nears, as Company Moves Further into the Clinical Trial Process.
“Patients and doctors have been waiting for these targeted therapies against TNBC. Now the first ones are in the clinic. I can’t tell you how exciting this is. These drugs or ones very much like them could be game-changers for triple-negative breast cancer.” Jennifer Diamond, MD University of Colorado Cancer Center.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.